Cyberna | Ultra-Early Cancer Detection Through Epitranscriptomics

About US

History

Founded in December 2023 after four years of pioneering R&D in applied epitranscriptomics for diagnostics, Cyberna emerged from EPITRANSDIAG, a multidisciplinary collaboration advancing RNA modification research.

The company combines leading expertise in epitranscriptomics, AI, and clinical sciences with biotech entrepreneurial experience to accelerate innovation and unlock new biological insights.

Mission

Our mission is to develop innovative, highly sensitive, and accessible screening tools for patients and healthcare providers, enabling timely and accurate action to transform cancer care and significantly improve outcomes.

At Cyberna, we believe early detection is the most effective therapy: identifying cancer at a subclinical stage allows intervention before tumor development.

Half of cancers in the world are
detected too late.

Late diagnosis limit options

Becoming the leader in ultra-early cancer detection

Pre-tumoral detection

Upstream of tumor-based diagnostics

Earlier than traditional liquid biopsy approaches (ctDNA, CTCs)

Detecting cancer before tumor exits from just a droplet of blood.

A new paradigm in cancer prevention

Cancer doesn’t start with a tumor. Neither do we.
Cyberna focuses on the process, not the event.
By detecting early molecular shifts in the cellular environment, we enable intervention before cancer becomes visible

Environment-based detection

Detects subtle changes in the cell environment

before tumor formation: Epitranscriptome

→ Captures the shift before disease starts

→ Enables action before cancer develops

Event-based detection

Detects subtle changes in the cell environment

before tumor formation: Epitranscriptome

Requires tumor to exist

Detection often too late

Cyberna shifts the detection upstream before the tumor even exists.

Science and Technology

Cyberna explores a largely untapped layer of biological information: the epitranscriptome.

More than 170 chemical modifications of RNA together form a dynamic barcode superimposed on the genome, allowing cells to adapt in real time to metabolic and environmental changes.

Cancer rewrites this barcode early, as the epitranscriptomic landscape shifts well before a tumor becomes visible. When modified RNA degrades, its distinctive nucleosides are not recycled but passively released into the bloodstream; their identity and relative abundance therefore act as an early biological signal, detectable before a tumor can be clinically identified.

An innovative diagnostic platform

From complex biology to minimal, actionable signatures: our platform combines multiplex mass spectrometry and machine learning to identify and patent the minimal combination of nucleosides required to discriminate between clinical conditions (e.g. cancer vs. non-cancer).

A new standard in liquid biopsy

One versatile platform, all cancer types: a single workflow applicable across all cancer types, enabling the development of biomarker signatures for multiple clinical applications.

Minimal blood, maximum insight: requires only a droplet-equivalent volume of blood, enabling home sampling and making large-scale screening truly accessible.

Designed for affordability: ~10× more cost-effective than sequencing-based approaches, a critical advantage for population-level screening.

Unlocks the limits of traditional liquid biopsy approaches: not limited by tumor size or by the tumor’s ability to release ctDNA or circulating tumor cells, a major limitation of many liquid biopsy technologies.